From mint · A Ksheerasagar · · 1m 10s
Sun Pharma to consider ₹15,000 crore NCD issue
Sun Pharma plans ₹15,000 crore debt sale to fund Organon acquisition bridge loan.
In brief
Sun Pharma plans ₹15,000 crore debt sale to fund Organon acquisition bridge loan. Sun Pharma will issue up to ₹15,000 crore non-convertible debentures to fund a bridge loan for acquiring US healthcare company Organon & Co. Originally reported by mint.
Sun Pharma board meeting
Sun Pharmaceutical Industries will hold a board meeting on October 12, 2026.
₹15,000 crore NCD issuance
The company plans to issue non-convertible debentures worth up to ₹ 15,000 crore.
Bridge loan for Organon acquisition
The debt sale funds a bridge loan to acquire US healthcare company Organon & Co.
Private placement basis
The NCD issuance will be on a private placement basis in one or more tranches.
Reuters report on bridge loan
Reuters reported the company closed a $12 billion 18-month bridge loan earlier this year.
LIB Therapeutics deal
Sun Pharma signed an exclusive agreement with LIB Therapeutics for lerodalcibep manufacturing.
Lerodalcibep market potential
The drug targets a $3.7 billion PCSK9 market outside US and China growing at 38% CAGR.
Q1 financial results
Sun Pharma reported 27% rise in net profit to ₹ 2,894.79 crore for June quarter.
Here's the gist
Sun Pharma will issue up to ₹15,000 crore non-convertible debentures to fund a bridge loan for acquiring US healthcare company Organon & Co.
